Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
KI-Analyse von ULTIMOVACS AS DK1
Wähle eine Analyse aus und der finAgent liefert dir tiefgehende Einblicke dazu!